// App-Quantinova.ai

P08.04 : Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors

Researchers

Presenter

  • L. Bazhenova

Principal Investigators

  • S. Ou

  • S. Gadgeel

  • J.M. Trigo

  • S. Viteri

Medical Centers

  • Drug Development Unit, The Royal Marsden and Institute of Cancer Research, Sutton, UK

  • Janssen R&d, Raritan/NJ/US

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Hospital Universitario Virgen de La Victoria Y Regional, Ibima, Malaga/ES

  • Instituto Oncológico Dr Rosell, Centro Médico Teknon, Grupo Quironsalud, Barcelona/ES

  • University of California, Irvine, Orange, CA, USA

  • Henry Ford Cancer Institute/henry Ford Health System, Detroit/MI/US

  • Institut Curie, Paris/FR

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Locations

  • United Kingdom

  • United States

  • Venezuela

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Epidermal growth factor receptor

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved